Dr. Carnevale Maria Grazia

Doctor

Contacts

Mail: mariagrazia.carnevale@istitutotumori.mi.it
Tel: 0223902288

Specialty / Department

Radiation oncology

Maria Grazia Carnevale is a clinical and radiation oncologist who completed her specialization at the University of Florence and currently works at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan.

Her primary areas of interest include breast cancer, oligometastatic disease, and stereotactic radiotherapy, with a particular focus on the emerging applications of artificial intelligence and predictive models of toxicity.

She is actively involved in multidisciplinary tumor boards and research initiatives aimed at improving patient outcomes through innovative therapeutic strategies and precision medicine.

Her commitment to patient-centred care is reflected in both her clinical practice and scientific work. Dr. Carnevale has participated in phase II/III clinical trials in breast cancer and contributed to the design and development of ongoing research projects. She is an active member of national (AIRO) and international (ESTRO, ESMO) scientific societies dedicated to oncology and radiation oncology.

ORCID Publications

EUROPA TRIAL: Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer.

• PRISCILLA TRIAL: Partial Radiotherapy for breast in situ carcinoma of intermediate low risk al local adjuvant treatment.

•TAORMINA TRIAL: Treatment of oligometastatic breast cancer-a randomized phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone as 1st line treatment.

• FASTPG01: Radioterapia adiuvante ipofrazionata secondo schema ultra-ipofrazionato dopo chirurgia conservativa in pazienti affette da neoplasia della mammella.

• RECARE

• “RAPID SOLUTION”. Optimizing Radiotherapy Planning: An AI-Driven Solution for Breath Hold Selection in Breast Cancer. Founded by Fondazione IRCCS Istituto Nazionale dei Tumori-Valorizzazione delle Ricerca Fondi 5per1000, 2025-2026.

• “TETRIS” Risk assessment Tools for severe side Effects after breasT Radiotherapy: radiation safety through

biological extended models and dIgital twinS. HORIZON-EURATOM, 2024-2027.

• “Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. REQUITE”. Funded by European Union’s 7th Framework Programme for research, technological development and demonstration, 2013-2018.

• “Mechanistic computational modelling of radiation damage to microvasculature and of its effect on tumor microenvironment”. Funded by AIRC, 2019-2024.

• Rosanna project: cardiotoxicity in young breast cancer patients. Funded by AIRC, 2021-2026.

• “PNNR-POC-2023-12378113” A Composite Assay for HER2-Positive Early-Stage Breast Cancer Management. Funded by PNNR 2024-2027.